Table 1.
Clinical and biomarker characteristics of control subjects and patients.
| Glomerulopathy Patients (n = 65) | Controls (n = 25) | p | |
|---|---|---|---|
| Age (years) | 38.1 ± 12.6 | 38.5 ± 9.6 | 0.830 |
| Gender (M/F) | 28/37 | 11/14 | 1.000 |
| Renal biopsy diagnosis | |||
| FSGS/ML | 32 | ||
| MN | 18 | ||
| IgAN | 09 | ||
| MPGN | 04 | ||
| Serum creatinine (mg/dL) | 1.1 ± 0.2 | 0.82 ± 0.1 | <0.001 |
| Serum urea (mg/dL) | 43.4 ± 28.7 | 36.2 ± 11.2 | 0.227 |
| GFR (ml/min/1.73 m2) | 87.3 ± 19.6 | 107.4 ± 9.6 | <0.001 |
| Serum albumin (g/dL) | 2.6 ± 0.9 | 4.06 ± 0.32 | <0.001 |
| Total cholesterol (mg/dL) | 297.6 ± 106.3 | 183.4 ± 26.7 | <0.001 |
| LDL cholesterol (mg/dL) | 181.4 ± 71.1 | 86.0 ± 16.5 | <0.001 |
| HDL cholesterol (mg/dL) | 56.2 ± 28.1 | 50.6 ± 9.5 | <0.001 |
| Triglycerides (mg/dL) | 261.3 ± 108.1 | 134.7 ± 27.0 | <0.001 |
| 24 h urinary protein excretion (g/1.73 m2) | 5.9 ± 2.2 | 0.08 ± 0.01 | <0.001 |
| Angiopoietin-2 (pg/mL) | 7505 ± 1354 | 862 ± 101 | <0.001 |
| Syndecan-1 (ng/mL) | 102.8 ± 36.2 | 28.2 ± 9.8 | <0.001 |
FSGS: Focal and segmental glomerulosclerosis; ML: Minimal lesions; MN: Membranous Nephropathy; IgAN: IgA nephropathy; MPGN: Membranoproliferative Glomerulonephritis; GFR: Glomerular filtration rate; LDL: Low density lipoprotein; HDL: High-density lipoprotein.